Core Insights - Microbot Medical Inc. has announced the commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, marking a significant milestone in the introduction of single-use robotic systems for peripheral endovascular procedures [1][2] - The Limited Market Release (LMR) will focus on high procedure volume regions to gather real-world insights and prepare for a Full Market Release (FMR) expected at the Society of Interventional Radiology meeting in April 2026 [1][2] Company Developments - The company has established a core commercial team and secured a third-party logistics partner to support the LMR of LIBERTY® [2] - Positive feedback from physicians and hospital administrators has validated the decision to proceed with the limited market release [1][2] Product Overview - LIBERTY® is the first FDA cleared single-use, remotely operated robotic system designed for precision, efficiency, and safety in endovascular procedures [3] - The product is backed by a strong intellectual property portfolio and a commitment to innovation, positioning Microbot Medical as a leader in the endovascular care market [3]

Core Points - Microbot Medical Inc. announced the third and final closing of its preferred investment options, resulting in the issuance of 13,989,115 shares of common stock [1][4] - The total gross proceeds from the three closings amounted to approximately $29.2 million, with potential additional proceeds of about $63 million from the exercise of short-term preferred investment options [4] Group 1: Investment Details - The first closing generated approximately $25.2 million from the exercise of options for 12,064,627 shares at prices ranging from $1.50 to $2.13 per share [2][4] - The second closing brought in approximately $1.2 million for 600,000 shares at an exercise price of $2.10 per share [2][4] - The third closing resulted in approximately $2.8 million for 1,324,488 shares at an exercise price of $2.10 per share [2][4] Group 2: Future Plans and Use of Proceeds - The company plans to utilize the net proceeds for the development, commercialization, and regulatory activities of its LIBERTY Robotic System, potential acquisitions, and general corporate purposes [4] - The new short-term series J preferred investment options will have an exercise price of $4.50 per share and will be exercisable six months after issuance [2][4] Group 3: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY Endovascular Robotic System being a key product [7][8] - The company is backed by a strong intellectual property portfolio and is committed to innovation in endovascular care [8]